Whitehawk Therapeutics

Update in progress

WHWK (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Whitehawk Therapeutics, Inc. is a clinical-stage oncology company focused on developing technologies that define tumor biology to guide cancer treatments. It offers a portfolio of three next-generation antibody-drug conjugates (ADCs). The company was formerly Aadi Bioscience, Inc., changing its name to Whitehawk Therapeutics in August 2021. It was incorporated in 2007 and is headquartered in Morristown, New Jersey.

Company score

Sentiment: 0.28; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: -0.16; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.09; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.02; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.02; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.13; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive